1_img1424895986.jpg 2_img1424896008.jpg 3_img1424896028.jpg 4_img1424896053.jpg
ГЛЕДФАРМ ЛТД intro pharmacovigilance logo-img
  • 1-img1423128723_img1424877095.jpg
  • 2-img1423128732_img1424877082.jpg
  • 3-img1423128813_img1424877070.jpg
  • 4-img1423128825_img1424877057.jpg
  • analiz111_img1422534233.jpg

FUSYS DT tablets


  • Treatment of diseases in adults, such as:

– cryptococcal meningitis;

– coccidiomycosis;

– invasive candidiasis;

– mucosal candidiasis, including oropharyngeal candidiasis and esophageal candidiasis, candiduria, chronic candidiasis of the skin and mucous membranes;

– chronic atrophic oral candidiasis (candidiasis, caused by the use of dentures) after failure of local dental hygiene products;

– vaginal candidiasis, acute or recurrent, when local therapy is not adequate;

– candida balanitis, when local therapy is not adequate;

– dermatomycosis, including athlete's foot, mycosis of glabrous skin, groin tinea, colorful lichen and candida skin infections, when systemic therapy is not adequate;

– tinea unguium when administration of other medical products is not adequate.

  • Prevention of diseases in adults, such as:

– relapse of cryptococcal meningitis in patients with a high risk of its development;

– recurrent oropharyngeal or oesophageal candidiasis in HIV–infected patients with a high risk of its development;

– decreasing frequency of recurrences of vaginal candidiasis (4 or more cases per year);

– prevention of Candida infections in patients with prolonged neutropenia (e.g., patients with malignant blood diseases who receive chemotherapy or patients with hematopoietic stem cells transplantation). 

  • Children.

The drug is administered in children from 3 years of age.

The drug is used in children for treatment of mucosal candidiasis (oropharyngeal candidiasis, esophageal candidiasis), invasive candidiasis, cryptococcal meningitis, and to prevent Candida infections in patients with reduced immunity. The preparation can be used as maintenance therapy to prevent relapse of cryptococcal meningitis in children at high risk for its development.

Therapy with the drug can be started before the results of cultural and other laboratory tests; then the received results of antibacterial therapy should be adjusted accordingly.

1 tablet contains fluconazole 50 mg; Antifungal agent for systemic use. Triazole derivates.

View instructions Dounload instruction
All Preparations